false 0001624326 0001624326 2023-11-14 2023-11-14 0001624326 PAVM:CommonStockParValue0.001PerShareMember 2023-11-14 2023-11-14 0001624326 PAVM:SeriesZWarrantsToPurchaseCommonStockMember 2023-11-14 2023-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares














Date of Report (Date of earliest event reported): November 14, 2023


(Exact Name of Registrant as Specified in Charter)


Delaware   001-37685   47-1214177

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)


360 Madison Avenue, 25th Floor   10017
(Address of Principal Executive Offices)   (Zip Code)


Registrant’s telephone number, including area code: (917) 813-1828


(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share   PAVM   The Nasdaq Stock Market LLC
Series Z Warrants to Purchase Common Stock   PAVMZ   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 2.02. Results of Operations and Financial Condition.


On November 14, 2023, PAVmed Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended September 30, 2023 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.


Item 7.01. Regulation FD Disclosure.


The disclosure set forth under Item 2.02 is incorporated herein by reference.


The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits:


Exhibit No.   Description
99.1   Press release.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: November 14, 2023 PAVMED INC.
  By: /s/ Dennis McGrath
    Dennis McGrath
    President and Chief Financial Officer




EX-99.1 2 ex99-1.htm


Exhibit 99.1


PAVmed Provides Business Update and Third Quarter Financial Results


Lucid’s quarterly revenue increased 392 percent sequentially


Veris Health commercial expansion efforts underway, with next-generation Veris Cancer Care Platform launching in Q4


Conference call and webcast to be held tomorrow, November 15th at 8:30 AM EST


NEW YORK, November 14, 2023 - PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the Company for the three and nine months ended September 30, 2023.


Conference Call and Webcast


The webcast will take place on Wednesday, November 15, 2023, at 8:30 AM and is accessible in the investor relations section of the Company’s website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-833-816-1419 and international listeners should dial 412-317-0512. All listeners should provide the operator with the conference call name “PAVmed Business Update” to join.


Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at pavmed.com.


Business Update Highlights


“Lucid’s sustained commercial success and Veris’s future commercial execution will be the primary drivers of PAVmed’s long-term success,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “As noted in yesterday’s Lucid business update, Q3 was the most important quarter in Lucid’s, and therefore PAVmed’s, history, as we have now begun to translate increasing commercial activity into revenue and revenue growth. Whether it be commercial execution, revenue cycle management, laboratory operations, or clinical research productivity, Lucid is firing on all cylinders. As we have done with Lucid, we are now laying the foundation for Veris’s future commercial success. This includes upgrading the Veris Cancer Care Platform to incorporate early adopter feedback; restructuring and expanding the commercial infrastructure; engaging with large academic cancer centers; and initiating dialogue with large pharma companies to have our platform serve as a digital companion to novel cancer therapeutics undergoing market surveillance.”




Highlights from the third quarter and recent weeks include:


Yesterday, Lucid Diagnostics reported that quarterly EsoGuard testing volumes increased 17 percent sequentially from 2Q23 and 137 percent annually from 3Q22.


Lucid’s upgraded revenue cycle management infrastructure showed sustained impact, driving $783K in quarterly revenue, representing a 392 percent increase sequentially from 2Q23 and a 930 percent annual increase from 3Q22.


Lucid substantially increased its clinical utility data portfolio to support in-network payor coverage engagement, with near-perfect clinical utility data (98-100 percent concordance) from three studies.


Lucid launched EsoGuard 2.0, the next generation of the EsoGuard Esophageal DNA test, which enhances performance and lowers per-sample costs.


Veris restructured its commercial organization, including two new hires, with expansion efforts now underway aiming to accelerate patient enrollment at small-to-medium sized oncology practices and to secure strategic accounts, such as large academic cancer centers.


Veris advanced development of the next-generation Veris Cancer Care Platform incorporating feedback from early adopters, including key enhancements for practice workflow and provider billing, with version 2.0 launching during 4Q23.


Veris is in active discussions with several pharma companies to incorporate the platform as a digital companion for novel cancer therapeutics. The biopharma module will facilitate market surveillance to allow these drugs to become first- or second-line treatment options.


Veris is working to upgrade the platform from an FDA-designated Medical Device Data System (“MDDS”), to a Software-as-a-Medical-Device (“SaMD”), with the goal of an FDA 510(k) submission next year. The upgraded platform will provide unlimited potential to grow into a clinical decision support tool that includes threshold alarms for faster provider response, analytical algorithms for effective triage, and digital biomarkers based on artificial intelligence and machine learning that will provide a risk assessment for cancer patients.


Veris remains on track for a 2024 regulatory submission of its implantable cardiac and physiologic monitor, designed to be implanted in conjunction with a vascular access port. The team has held multiple, successful FDA pre-submission meetings on various design features.




Financial Results:


For the three months ended September 30, 2023, revenues were $0.8 million. Operating expenses were approximately $16.3 million, which include stock-based compensation expenses of $2.2 million. GAAP net loss attributable to common stockholders was approximately $17.7 million, or $(0.16) per common share.


As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company’s financial results, the Company’s preliminary non-GAAP adjusted loss for the three months ended September 30, 2023, was approximately $9.7 million or $(0.09) per common share.


PAVmed had cash and cash equivalents of $26.4 million as of September 30, 2023, compared to $37.2 million as of June 30, 2023.


The unaudited financial results for the three months ended September 30, 2023 were filed with the SEC on Form 10-Q on November 13, 2023, and are available at www.pavmed.com or www.sec.gov.


PAVmed Non-GAAP Measures


To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.


Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our unaudited financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.


Non-GAAP financial measures are provided to enhance readers’ overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.




A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three and nine months ended September 30, 2023, and 2022 are as follows:


   For the three months ended
September 30,
   For the nine months ended
September 30,
   2023   2022   2023   2022 
(in thousands except per-share amounts)                
Revenue  $791   $76   $1,403   $265 
Operating expenses   16,319    23,443    53,815    66,751 
Other (Income) Expense   6,222    6,565    9,443    12,180 
Net Loss   21,750    29,932    61,855    78,666 
Net income (loss) per common share, basic and diluted  $(0.16)  $(0.29)  $(0.48)  $(0.78)
Net loss attributable to common stockholders   (17,748)   (26,197)   (50,365)   (68,732)
Preferred Stock dividends and deemed dividends   77    71    226    209 
Net income (loss) as reported   (17,671)   (26,126)   (50,139)   (68,523)
Depreciation and amortization expense1   733    700    2,207    1,731 
Interest expense, net2   35    471    162    986 
NCI ownership share of Interest and Depreciation adjustments   (159)   (136)   (470)   (312)
EBITDA   (17,062)   (25,091)   (48,240)   (66,118)
Other non-cash or financing related expenses:                    
Stock-based compensation expense3   2,245    4,764    9,171    14,583 
ResearchDx acquisition paid in stock       188    713    427 
Change in FV convertible debt2   4,392    (261)   5,772    1,739 
Offering costs convertible debt2       1,232    1,186    4,332 
Loss on debt extinguishment   1,764    5,123    3,032    5,123 
Change in fair value - derivative liability   31        291     
Other non-cash charges       25        82 
NCI ownership share of non-GAAP adjustments   (1,040)   (864)   (2,733)   (2,721)
Non-GAAP adjusted (loss)  $(9,670)  $(14,884)  $(30,808)  $(42,553)
Basic and Diluted shares outstanding   111,941    89,759    104,516    87,724 
Non-GAAP adjusted (loss) income per share  $(0.09)  $(0.17)  $(0.29)  $(0.49)


1 Included in general and administrative expenses in the financial statements.


2 Included in other income and expenses.




3 Stock-based compensation (“SBC”) expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses:


Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses
(in thousands except per-share amounts)  For the three months ended
September 30,
   For the nine months ended
September 30,
   2023   2022   2023   2022 
Cost of revenue  $1,779   $1,626   $4,809   $1,996 
Stock-based compensation expense3   (32)   (9)   (86)   (9)
Net cost of revenue   1,747    1,617    4,723    1,987 
Amortization of acquired intangible assets   505    505    1,516    1,278 
Sales and marketing   4,016    4,736    12,893    13,559 
Stock-based compensation expense3   (403)   (643)   (1,302)   (1,859)
Net sales and marketing   3,613    4,093    11,591    11,700 
General and administrative   6,858    10,374    23,916    31,254 
Depreciation expense   (228)   (195)   (691)   (453)
Stock-based compensation expense3   (1,499)   (3,854)   (6,761)   (12,016)
Net general and administrative   5,131    6,325    16,464    18,785 
Research and development   3,161    6,202    10,681    18,664 
Stock-based compensation expense3   (311)   (258)   (1,022)   (699)
Net research and development   2,850    5,944    9,659    17,965 
Total operating expenses   16,319    23,443    53,815    66,751 
Depreciation and amortization expense   (733)   (700)   (2,207)   (1,731)
Stock-based compensation expense3   (2,245)   (4,764)   (9,171)   (14,583)
Net operating expenses  $13,341   $17,979   $42,437   $50,437 


About PAVmed and its Subsidiaries


PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other majority-owned subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.




For more and for more information about PAVmed, please visit pavmed.com.


For more information about Lucid Diagnostics, please visit luciddx.com.


For more information about Veris Health, please visit verishealth.com.


Forward-Looking Statements


This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed’s and Lucid’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s and Lucid’s common stock; PAVmed’s Series Z warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed’s and Lucid’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s and Lucid’s clinical and preclinical studies; whether and when PAVmed’s and Lucid’s products are cleared by regulatory authorities; market acceptance of PAVmed’s and Lucid’s products once cleared and commercialized; PAVmed’s and Lucid’s ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s and Lucid’s future operations, see Part I, Item 1A, “Risk Factors,” in PAVmed’s and Lucid’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.


Investor and Media Contact


Michael Parks

PAVmed and Lucid Diagnostics







EX-101.SCH 3 pavm-20231114.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 pavm-20231114_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 pavm-20231114_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Common Stock, Par Value $0.001 Per Share Series Z Warrants to Purchase Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 pavm-20231114_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Nov. 14, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 14, 2023
Entity File Number 001-37685
Entity Registrant Name PAVMED INC.
Entity Central Index Key 0001624326
Entity Tax Identification Number 47-1214177
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 360 Madison Avenue
Entity Address, Address Line Two 25th Floor
Entity Address, Postal Zip Code 10017
City Area Code (917)
Local Phone Number 813-1828
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, Par Value $0.001 Per Share  
Title of 12(b) Security Common Stock, Par Value $0.001 Per Share
Trading Symbol PAVM
Security Exchange Name NASDAQ
Series Z Warrants to Purchase Common Stock  
Title of 12(b) Security Series Z Warrants to Purchase Common Stock
Trading Symbol PAVMZ
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001624326 2023-11-14 2023-11-14 0001624326 PAVM:CommonStockParValue0.001PerShareMember 2023-11-14 2023-11-14 0001624326 PAVM:SeriesZWarrantsToPurchaseCommonStockMember 2023-11-14 2023-11-14 iso4217:USD shares iso4217:USD shares false 0001624326 8-K 2023-11-14 PAVMED INC. DE 001-37685 47-1214177 360 Madison Avenue 25th Floor 10017 (917) 813-1828 false false false false Common Stock, Par Value $0.001 Per Share PAVM NASDAQ Series Z Warrants to Purchase Common Stock PAVMZ NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 3 21 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pavmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm pavm-20231114.xsd pavm-20231114_def.xml pavm-20231114_lab.xml pavm-20231114_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "PAVM", "nsuri": "http://pavmed.com/20231114", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "pavm-20231114.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "pavm-20231114_def.xml" ] }, "labelLink": { "local": [ "pavm-20231114_lab.xml" ] }, "presentationLink": { "local": [ "pavm-20231114_pre.xml" ] } }, "keyStandard": 21, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://pavmed.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "PAVM_SeriesZWarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20231114", "localname": "SeriesZWarrantsToPurchaseCommonStockMember", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Series Z Warrants to Purchase Common Stock" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "PAVM_CommonStockParValue0.001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20231114", "localname": "CommonStockParValue0.001PerShareMember", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par Value $0.001 Per Share" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://pavmed.com/role/Cover" ], "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-23-041370-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-041370-xbrl.zip M4$L#!!0 ( 2H;E<0_O?88R( -YE 0 * 97@Y.2TQ+FAT;>U=:U/C M.)?^3A7_0=O;[Q1=Y:3CW&EXJ>72/<.^]!5ZIF:_"5M)-#A6QI*A,[]^SY%D M)R$)Q.F0.."IF@827\Y%>LY%1T>'OUU]O#C:W3G\[?WQ&?PD^-_AU?G5Q?NC MP[?F)WS[UGY]>/+Y[$]R>?7GQ?M_O^J(4+TC;F6@R!7O,TD^L3OR3?1IZ)@/ M''+)(MYY!3?"K5^RWG= ^C3J\O =P4O3_P^(8C]4B0:\"U]Y+%0L>G7T2W@M M!P>';[\\Y')T?O?_3X-5=D?[_L'KX].7KB%Z^5R^1EAQ\^?[H: M?T.I0_L\&+Y[[!WZ6LG_888D+; OQ[_WF;^[\R42M]R'NT]BR4,F)?D^\*EB MA(8^N>KQR"=?8QH! >0##VGH<1J0;TS&@9)&T$C5NN2].A$DFMM.Z@_/CRYB MC_N_1/+O6!S(W9V_C9*"(8G8+0MC1GCH18Q*YI/:?I4,6(1D$,G^CN$G:#$8 M'KX]WUK]@002%6XU$[_#5Z"^WQ@-5(]XHM\'1>$<8S\&-)114YBB,%=/:<3(EX JN+5/ AJ'7H^'71@4 MY&M]RT7V+/1^*L(.BQ@H:W?'@\FH\?:.77M4*J($N6:DQP(??NV+*!)W#ODD M;EG_&G3K-@XOOW\Y4KW#M_B34$7:[VH5WW&,./)IV M0P%R\T *.&!]WN4*+N@9^)+,4R*"[Y3PZ9 ,C&\!9%!RG;@7L7$O.I8/RX!^ M&@>0D_&UY/">B*.DM9$C9Z/7:IF-Y'7Q_?1L)"AK$HTH]!,-)AIPW=TQ]]J+ M]5=C,LD !-,YD#[2E(C M%3I-HC,^JT?N-- C.49!"O%Z0&\!"LL E C797(<@.$+X5&W+!@BVMF7ZF=Y MZ3@CVK!?#T&" 1OT1 @0^KU\62Y=:[<TGQJ9)%:\%R(F%@G8_TOPL,"V#9'_002!N .SO;MC->D%L1P;W?=TBTY" MQ&!^#3WE(>4)PR:-=@.L%TDSCY?G[ZC.9.,4 V9_R2J;N[8],[O_%N M+\#TV1JS.(5FILB?<%R3V2/A1134Y8_G V1L3$SJUB;7DTZLXHA-Y@Z8%^L) MFDQPG*6#B .70^)'.D+ R9N$%O9)@0B[)3 V_>1MCL5XH(F"(PZF\(++'@W) M\0V$#@[Y6#[3$8QS_TFG/\-T3=,O*YTX%P(BHG]N58DE"@ MVPWV>@A0PR* G_11)@:X3@>P"2 <\K5&[J@QN7T(#@CO#T2D:*B(S87AXR8D M:[Q\N"%B '/L'LT.Z7&$.3#H\-@[B+\IT!J*.Y!?-P[1S*F(AA(P$!P6FUW# M8&E,\!1@\9:K(=ILD6;B\*W)[UV(Y56O3/[H,20$8AY4SRS=.>D]WM #9 9I M0@#7AP#%(8#50AOPX>Z.C=H EAT,#KV ASIHPV"&1EX/#;\?6\*2D K\I Z/ MD'H8)&COO2' M]5F?>V!%-5$F 2(/C.<9F>C&1G*[.^;F08_"A+#!-@2WR(26L8@C M='8-9Y)%\!&,/YK&UO8.H4=@"!YPD+P?!Q =L%@'QCH[V!7X?ICE-TR!E.%9 M,/_QXK*=R-N+E+. 'ACXKU*)?. L\-^1+S ]#N !F.#V\$92*MDEM,.S\]\3 M,@S]I6NAE.B_(\V!.B PFT!ZZ6&TH2RLJ>+.6TW.5PM@8>HN#R(R;%K7JCK&;U$"\VUJF9^LLTUR:FC!9^#4SN)+^F>!<96*J+?[4&9,2 MBPK&)N'BS[*,5E\XK'V9^) .[9Z M9,'_IE/M$4.'FJ''3%.G&ARM]U+\"G_ Y_ J]#=N11 CD:,59[/B++I#4Q'//G!J_W(BW,3M_!Y:.#$U4Q"7)-H-4] *)DOU9)[LA&C,&KT5L*V"I@JX"M MIX&M;#,3RPTP9V@F_,B!P5*$-),6*QY@4L^GBA+TB3HBX +3,3(>X-]P8RED MZDY$-Q Y#S$+)V"@ .)EHT8GG6R*S]9XT:@$D--AGII#S]Y^NP13(X4R7/Z! MN!N3/F^(C; BEI$0J6*?,UG 4P%/!3QM$)Y,X2;@41IS5]WH ,SV$AXR>'<*0P#4=SZQH!."W11(_ M+DG:'P283I>JP(P",PK,6!FUMCP\RSP=+7HE?LQHE4M$71KR?ZA97S1Y5;T8 M=B< 4.Y(CT=(C?8]I@K0LY&!2X1)Q3JAO*]?8PJE J:7[09 !GHL+(Q$$.C8 MD"HB^^"*P1 O8?%IW"%@/*,.^F%$1 M :)34CBP1)9ZH@)!CB/K#1LF_A82:0K)$Q C&#%VP)&RY>>Z0#,BUSR 4*^; M,8&O05N7_@/3X":.[?KQ30%$_>MX!7J!8 6"Y1;!4OAZ=M"E"YY,H1@C/I=> M+*6NJ=7S5S+,&P4SJX7&2YYT/5\"8^/E0MF(&=46(2S-+2["0BT&L"0L67WA MQP$SQ84=ZF$V"HF:47>4C1ST#[&6&5\N03I1W)5F,QP0RK!B3:H2%KF!'R=" MOQ3@EAL5,:J, 1CH,KCG#W%%!+K-V/;LO3. .'1L;,1G5P0G(4M[330D'\Z. M2SZ30#S%2H./=L/AF=YP2,XPP7TYE(KUTWU['\_.+M-M>]GAA5R*CKH#+[!$ M98F6[ M+]H7)2R[IQ[/1WL!TDTQ78 S=L823AEO9NWF#:PA]KD$\8X2,&;PA MN(X&7M.5TU1(&E^3;3MQ&$ 0C4(:"&66*)$AK"F\( MEP6BR[ULE/1%R.%=#C%FC_FVVX-]D=D% ][M7Q"\VRT\8'THN:40*@#X)EM- M$:J-X5",]DF/9I2([B[1CP/%!P%SDBT9G3C0IFT !G),&'W&,$6BY7=+(RYB M:>DG'?"^X^@EK!4_A'0/[T2H%CL1BIT(Q4Z$?!7EI^W,=G=L/[-B@\%S]KX* MQVL%G0:BC!%WVB'GD<8XZ697W'L:,?*Z4FZ3/JZ#B+!,/J>-B=B/ 8,0,Z.O MHQ])!Q"Y_>!]"G'AD+QVF^5:\H:D,,;&NT0JX=TD73I$'U]IUI*2UZ-W^+I: MKF9T_1)^?CT^_@+AOR*!P!W="L+;Z]CXF. ,XGH]AN-(!,;<&.'B3N?[#+3* MK92!;(2 [_MZKU)VFV^P?"=]88]&;%UN7#6??ER!F05FKA8SCS-B%>Z'""$@ M3%:%DT9C@S@:",ET7!H$L2YA2?:QFT09?C47N>!1&3%"MR<(15CRJ-30B$LP M=@^]!<%P5O>7Z>9ISNPF,5FH@7@4TY\A]J] FC2"4A_UQ7P#HY,=V1ZU-U.( MFHV@U_LC]$WPM+)?X&F!IP6>/BF>)LW(LDS6'L5N:X!B"%_Z%_9WS&]IH"MR MM"_7+-?3Z4SU9[- 0Z^71R9G][K66M(!M"_XWSAD,SI#%CA1X$2!$S]-K6XK MF65RQB&-??YP]]>%? L3;G9X -^:#D!9R,#77+X_1>?J RX"NY725_QCU/NR MEO:^Q%VIT7CW/ERCO+LKCWKNH6N"GTCFE;OB]J6CS-8D]("+Q-!]2MS=CXQ* M7&G9:L:*3&6!_NM ?Y%U'_!@$)C^!-B/[2%;,.H2KNLXD\VV9IT6V_O:77FX MH1C7:L$\9'17[:84C.X'$03>N$(KR1Z"P!MGO)7"(#F\Q8-12(&<-#0>D=VW MJ $>9W9#]&AHKU>@)7OPQ4E6-4EX9B/#K .:)LAZ#Z.B/U#S/G9S\#@U6YFT M*>P+F(MFW]R?G5V;-K S\X89*VOURGB3ASIQ(AYDB3F-=I!>"QK[)@\ M1=)55\I8CYNL.?6^\+'&B2:[/CT1:A!"^Z_W-W&E>^?KI!%,#[C<(UZ/AEW= M$+M#>40@](G9O9LS3IBQ-YG=H(8UGUTK8!@';\QE#X>IJ5) +9KVA*L3(8=3FW#1#-A\;:7[AH5)K@PP2LUP8G?FG$[U30FX P> M&=VT&!!H,)3J>U0KJI+9=E33(;Q8*0/"^;2H]SX&2N$G$ M;((#.1I9V(P:ER+,Z!< *_@BT[-9%XU/NVK:*T"M_).LE&C0#W3CXG'56:KM M?1D72CHC92_D#R4620]@/RD -,*T9S7@U_!11K?1=+/A*C;GZV"Z,I18FJW[ M:VE? *:&F/R<@?C-BC+6Y.L6TK@R@EVATT,NLFK&&77E]CD87A784X8BG:68 M(YC" A<6N+# ^;7 YC O1"N[H3D!?1L>$MWS*@@,R&);+6V3+;9"N!!E;IPW M&]*!@L3.)>'8N)'3VS ,VNC-(W;E'+#Y8QHZ9XU!M?TUAPTL8G[!99AA>L(5VLD1\::9@J8$[&=RG)\I9 MU]%H0>^^'9G='@L&FBHSDL=&[EA=169W &^=$^K_3/2>U8.='^I/O>F!Z#TY M,P,'B=GAY6<>(V,)+;//V!:5 %]1UQ22S'2IR^0<_! ?'$F=Y!F;/\F,S-J3 M9O[82S#-G@NA?1739@]DEPYR/;LP\8:NE-'/2_=;'M[Z4"NV/A1;'Y[=UH?" MCR_\^#66D&;UR+ '+-BNU/%\/!JW9E!O;@ZE3=)WLU:QP6]742F Q!_88&=OM\Z1F>QM6U+/8B$5$\4J#^@,&Q #5 MJP3[00'C-F(T!0?H_(7=%-BT-S!A4-(GD-//R-JG?[]JIGQ-GU:^B)?Q87ZQ MS^')MZ.)\9B=X+QP-SW15L$<3J,5Z5X/]#N&9P7A38%_0)826/75 T]<3H8( M0@L)QT[7\7?.&PSY9K?ZLM@MM+L,N\M,_OE@]NIH3SL-(I9@[@&D?F MC>DW MW=.FO*];M[Y)B']4=/=T\\"?6W;[PH*'\0#Z[T9X7B>:>Q&](U'W>J]:J3O5 M6MNI-AIO9BC'.@'U-$Z<' /?S-;-^X/(WE7]UYQ!?2\"^M>LD/+UG(>Z]R^/ MD*!71ZU]=]X=,Y\_>[9NA/+FEA+N.O7*%%YN">W59F-IRG]JTOW1XXK-F&F/ MH+JA8GH[],,H,@-B'U+$+!TWG9J[_]"%LQ[X5-1 !%BO3PVY35'3J#EM=VH8 M;8J:9M-I-:8P\ E'\@+F8X%!/=<=^JR7]_;.]?;3-^2]&? _$TE-QKQS':/% M@2O;DQ(].=6%W:Y%"=E&*32F$?C%26%_%IR]."FX5<=M5U8BADV9YKDH]HDI M(%;,7]*SG0K99LA7]RIZW*=])!/TLR14%PB GIB$ M>GOC)+06)V%S$?*G#+VUGCHBVW-;3NLI%;V*7\$K$.B["$_Q(',Z P5IYBHEQC,F-]/!XI^? 9V-BI M4X.M,JCI0;XA&^W6GM#GS62C&]-K\FNWT4?'>H>!WL+X[JF9?OS" M=2XK%-2LEIJU8>^,*NV551Z>C;7@F.[ 8=.SN4!*8#VD[+<7\ 9S85OF+W^=GA-Q%[)(]OC ))!QIT$Z ]!V M3!J3D:.U_?':GMM8/F![\QSXKRT?M#\'_NNMY1=,GP/_-7?YE=(UI5UG5+6: MUF+KR#Q4%C$V:\@\-)S*=/GL)BBI@Y[J"SC.:\@\-!W7W="*5X[#UX*:;:$F M%_4$GR?/$A%I![6PBUM!]='/22ESD5@KJ'GIB;7+1SK)ZBQ!;:U9@BI8Y/PD M"IQ6LYX78O8=-T=YB[K3:&?,?N8CL?:-248CKW?V@U#O[YA+W?2'#"C7S0-T MQ3,PH*T<#5@WZTK'D\);5LELT,Q7E&"D1_S6]+ -N&W4^>0*S4V4ES,S4EUDU2#'DMD@5QF? MDFAKWVD^7J=477J\YIU]M^ZTVX\BUO/EOU9QVI6I]8:7PW^]ZC0:C^+U8_SG MP0-[=722]F8X,[T9C+NESV5)SN5Y\L20ZSK[]=P$ANU]IS5=AKNQ7"=HN;%( M2XLU":<%ECIC%F^#0?,\"YSL'\5F)7K +RFW!3MA3&_#7=V:TZ)=49ZPF<,6 M=459G(1TU#ZC5O];0_[AR9'9#0A$VU6WDZ/SL1,B[,'I9B^AW^XI:4 M!YJ#)-C,8T7+6RN9;5>L7DE-M#JN46%/Y].XC&I-]/C,=/7P(5CUXA"L,:_A ML#@$ZWD<@H63/6%KHHABVZ:TJ:=-\&MN]>W>+X&/!YU>GIS^$NG?WB1X-G'0 MD9CJSXWG3OI,41[ %:,CB!)C9MJ373/XC%P/=W<\L&A=$0WU8>>S'YBE:#VYI_2 ?6N4Z*^#9RO$?S_EA8,%F=4+/,J4\+A>%_H9)O9Q_0L?Q[/9AB86M_=-@9>G 96,(D>Y?.!Z[?[]@V?4W2* M1V#JTYQS3M]N">VNL[^_O-R?Q6Z8 MI]H@N>F*B0R-B'/.R]'+#47&2M<9M8JCNM%6\6V3A+X!FT-[DY=EU5VH]>N-:: M\8*:E5*3BXXUQ^.=;,'^Z)8$D4[O*QIV]1Y2*B533[Y7HU')S>Z(')'BYJE\ MRG6JBYR*4\!N04U^J2'R0!GW2Z5^K&8*WJ MM/=SLYW:K3F-K 6\1:XKQ^F(&:?&;VMFI;G(:>3;P8KKU"K/)@F)IY-N8]9+ M+FD&-YZ J#G-%3<*VSA+X!^LV ANG"47HJ<5MVS( T^9SUHI@K""FGQ1DXL@ M[->YNS">6F1-L->Y:7GI5IQ:*S>MK:HU9S\_<6K-A1&V/1L&)\Z62<*F)Q;1 M7K6:BS.?W?U\'+.*!()RT=Y]?UG4VY2 Q.X +!N!S--I[6Z MQKR;9L:M+I8I?LJ^-8NG$.9OI=V.>*[AN"ONM[AQEII.;<6=[C;.DMMTZBMN M_[IYGMI.JYU13T]VXG1^0]6"FFVA9E,=U$9G>F@KY+-;%HC!.II2UQQW$;]C M/2IK.M5%5E36EM1HMG,C&H#:9E;S441EVQ&5U=QGX_E7%TE*;@W,=O.C4W-XU7JS6GODBQWGJH:=2C*I3K3QA=]H,"^!. M:Y&5A/7%"45.8?D#)18ZA'H[HM<%#['>#F86/ 1[.YA9]!#MW-6-+^G=;?+< M!;?FU%9\2L!&V8& =;JAT]:R4Z\Z]5H.^CZLB)U&)3L[V]TQ_O D9>9DB_OS MGAP=7XM8[>Y\.?Z]CRUTP)DK:4?*.6W9WST"MC MKV-*? XV4/(.-RYHGT78K+\D%7:UAFO1.@)57B\$.]@=:C>5AL,Q$V9[(R?7 M^NR6>\R!!]-N*( ##^C1V73>Y9C:Z#$:J!Z1S%,BDF4@!@9(G_XE(JZ&)3QY MT".X6:* X^&'HO(0/L>V"\2(,AF-L$25$ M8+I*WW&?26",^H31"*[RF;(/%!W"1J_#F-N(00G2YXIWJ6*:NXC+&WGO:GNI MSZCJ)=HQIP,\H*/?8;Q)\IO1+*K'24;7A,Z3P=,17HPQ#T8Z80]?Z&-#82E" M&/K_X$@T1'C87UCUP!'K]G9W(M870/@ AAWH$COKL@_*((.AF0@(N7L[MSUN(=LP7CBV"JU M0SUF&$'U&NI.C2Q/499? JI@[/1?U*D.C>)4AS$?Z; XU>%9G.JPY9[(!Q'M M[O1%9$Z;07NF_^ API.%970EB7%9'#((&)6,W'+)%3G\?C2@M_!Y&9#\\.WW MHV<&:-M#_DB/TZJ;\MRFM1C@)?Z/0HTY5N.XMP5O\UOAWA18W'W^#(N\@ M7BE="'$##NCNSF5Z[%H1>&^._*L>E[L[$(E!\($Q"!T=1:2C.:VSP.AL[*0\ MH@-2'MZ*X#8)U]!>QNC2*PH^/\8I:MX($P.P(9 >$(29QV9'B3G*8TG.M0T]OR7 M2.*Y3$ ,7J,-1?(1:"@$YPO?Y>B70*#Y%SP"@Z,Y$DA(\D0<8/ (P24!7F+@ M"20>!TH?TN/S3@<"H4X$X9T^FG"2Q=V=L1,*R;?9;R(V0S"T;Y$H*_-@##9D MHE0'E[9!;"9RQL.AND EJ!$$$4 ,G61-!B!YMIA8,&8%.4M<,SRX=[T>=_#V M_R/ 402QHSQ(=Y;A.4:B;\\9-KD-#%=]KE5RH,F8Y)&'/61'[>X E?,J(AW+ M*@X.K7MA,Q8*9@+<9?MP@MRI?XLAZ'V2ISD<1,*//:.LB'5C$):(AJ"7^+K/ M)03.(00,/:9%.OJ>T%CU,#&!I.M0&$)H7$>5.JF51L,FR-9-0N'-R;C0H^%1 MRKR 8[8@,'K!A(K] -0!(F!R1!A> +^'&=C%0>X!)J"\KH=S6#M(=$<]/( ) M);J[,S5P'GJ-0"4D[\'K1FDE3+I,C:GI1]%K,WA1/Y3C)//-,$+)=&)]7C4> MFQ8RYN,#=0)+2T6O;BNNCP@=&T0PT<[#]"D.W'@W;X[K242@!1Q)G(/% L@)U!//O>4QD="22>.-"T!MR,51H07\4&2,H,O)1NCF?<0R6!JT$B1< _X0]]@A M]@0[1"'R@>I,J6//LD/H>%13?9R-,$P1C8_#,$8%?6/(#R;=0![PFDKI/Z2C M3[I+Y\@E P@W,TDG,W]X/1I"('P*(\7,0 ?UBY=*"G)'WF&VQ0.?*G.FGN'D M$58L)QI?T#A]C>$NACG,:1J_6AIA8MA%!5"FB2QH1Z&:U"QV[9/*9&PEPMSE M<^D%E/?UFS%KIO/",),#A$\.?'A!EV,/W1NQ6#WN=PYQC( UZ M=3"YJR^T(@16D=))X)X9NO[QE(C9R3)A+>L[L#5.%X-]J=83:+O)2'W$28G98"S ($WT]:U?BO-;?7A%3;-C/1Z& P MB SB$5IJRBGM2F.C4EG09CQMI1']< M#I^5CJNV+8T$JK(G/I)X= XTE"J3!M.5DU&W,%#57ECUP*UJ^U4)-1*BD'J. M#K?&N,%P65V!T0P]Q+>GC'V<4(!M!#C?D4+=Y:" M34:AU*_HT'!7DLQQY8Y$V[RB5Q" "L\L0\-T86U>$JBNV%;8'IF8+B8%BJ.L MF+41P['XU+#(AJ/;UFAQ7[W" "IJV?-$P<- I7KN^G).H^PFE/6Q+B$$(XR>']$]">4.WL6Z'6]"1$)+= M;RNX>,\Z>C_IX+W?P5= 293&K=[2_.#P'@-/ O7P M+]?#N@(_=DF3NO<=2:/X-:"$*5!%':9BE =8EJ25=04/+_#H/@8B,"DFXF+R M%7"3IS#*A7OAWA,G+@)X]!H8XGU3E2Q,[\5[+CU=()0_>PV< J.E[L&*SY&T M%'C;4$:(VB,-GX0ZP'P9),1,&[5(#ZI4\0 UC)ZD?W,?? ,"+-+A;*Z0OM]. M(=34I%$&Z8:.>2$99AB_8HLM!/Z-* K6^;)@7Z%BU>D!+-GE^*'=8/(F1VL= MQBMA00C#:D(Z]!3 8Y()<$ HRUG@.!J ]';@"WDBE)TPQ4),T4"W&&*0BM@" M18VI6X,)WPSE6A4H0%Q59E0N6=G:"OO+(C*D2L@K9O+L)$1)S]2PN_0]5$'@ M+CIJ.):/#:KQ.NS+Y;\JIAW?/QT_)PHK*1#L(4X^7BAFLJ7+X*# M--MX@BZZ$)^'S80Q-91Y*L!6L.R"9./LI L^I$G97#-@E"6-_))9L@($^ ^] M85P^MB7+Z$UP3'Z[EQUJ@\S,&[V>H3=M0WZL2]:UI#DX%H'1JF.++]-+W&MC MZZ_-R628<9+Q^)+8ME')VX_ 4&P1QC]+!$'0MG/$- M J_T9AP3H)UE=HF<0JSK^ M.4*,*<.21KI0),."8A+JF)J2/HTAW)%Z1 -[\C%U*?F&7)(#4SO[WWT(R M=G0<;8/3Q>#"AYG=M$XL(G_*"V@X&@[7I2YW@J8-<9?>L&V8G.8C-""*K3+ ML?_XO0E;I*O:7KGWJ&W8H%;XLU 8-NP@!U<@*>:)#^B! P!-32B'"&OT&_L ME@N1@TF-.7JF.SN%_WF68Q?]4HM\K%YNY.KEI Q=O\>:YZ5D3YVN5EN=DLUZH;VD/1Z^%- MKGE>KIZU:M5ONSN%/!)C!XG##>U30$!L'/4^SY5JC4N@F(-DU@T+ZAS&"CQP M%0X7#-EA)BF+$=[+X[#:),#V*V8J8F\@7LM=\/+?% 29QA'*IL,7LT&/\>AN MV>2O*0L03(UBM;6[TRC6:XW6)L\%]*9^U6A>Y5AW6C4$4K<%DA4)<51K(.%@ M3]E'M1)JG1^P! M@N]8 E\)4QOA/B!%%B_&RGX&,>-\&C\G4,&R8?$$708Y.MC$+'WG$SJ1YKD9 M:5[GCGO1=>L7B_6S"CZK_+I\T!*=5XEU-V-X$B)#.Z.P" K4515I-(*>87V1 MV \0$\I6C;X;DQ$2WQ"#O%0;?%*E8$MM#0,V38/G,D^\QT+\NRDIBO_]U3T, M.&2> R4;FB:9% CR?W,C&L>V]7H$?6S91)8T?[S ]_+C(\>V,N/7^4Y6>]YU M>SG&=[>-9M=1PEM';MJF@;N$LC2YS?)BBY>1*%9S]N#BVOX9?Z-UM B7&X)D M;@\;W7(U'WF)R60K[#_KO6=X#>:/KZZ]XE"2;9<\-FB(BUM_&)%$4=/$,HL= M*XCH**]*(&FM_<7#%>6K,KM"X;(5).LC2+PNQ<7_?$2(;4:HE )"I:R#1C<] MI4);(F/*IF,LEVV)+3;U55;,-02PW8&/3,OI,^ 1U]0MH Z,& M:]( M/P+9=$?" YOOMY_NF86UB*J/PT?%@)\6"(:A@D$0VPQTVFQ\K6";_5N MXW5,-\M3$SPLO2>$XZED^F#+01O)0<4 ![6D8=G+SLI<8CS'3O'.]?<;]3NI M]-\:17H6:2B;2(4%44@(J=0&FDHP))OBT^QQO3"=:OS]'\-"-5L%E^^[8Q&J M$)E-7,":X>.V*4-@=#R[?%I=[D_UYT^%UU^76)^1;]FV#4+I1G,>4Z:>P\/% MWI;IUGN^]LJ-YNM$9;%G:L:([2G:5!X-JF>/6XW('*MN?>\OY7LG#I^U6"=& M9BI@9.84Q<*4>A\5HF-AL8&95MN=(3F3B!U:F?G[=C-U =FA;#P9!.3PS5]@H9^1M:EC981K.X)!ZA%6,#A_1[SI^YA@L0AK+BP3%U MS*RM^KO+V+>29AC62_($6Z?Q[4OP0YQ&;[+K!K4E[8Z8RZ->JJ8U4[A\6?J% M5\%E 8RA+$A881,]Q7>W6+SA<@DT.JAN$5TFIJ2AXA#+CDWZ&-4ZH-XQW5]1 MK.:OK[5U(74/V-,ECC'I)\I4;(KM.DD?_???:5%('<$ZL+&&3=70,=*YS_4- MP8+0'&;C(?),7 '(Y4*QGKB[+9OYJCG0WB@4IW$ QQT* MJ?TE8G#.7! \,BL&B+,Z&Y+G(GY"0GI\>H@KY5+RC:3.X@EETP)42XOI[9:! MK;?Q-P0T+/)J-/>E[8.28<&:F\ZZ6\A]ACS3 01DAV7;]2Y64!.$)485B=K> M5JBM5GM72O,JEA]!::D82:9I&:9%V,ZSMC%$;:P9 S8WK)!-&4J'+U"':$R3 M$0IJS<:@HQ3@0$1)S]%L2<>&0[41HJ##:&?$6WH-C#:P&%=MS$ID!=9D[P77 M=;L[DC[R"SL@3(P!:\@2T(2%82G:HQBC,ZQC"\S+L@Z-'9X:0+F(&''IW<]L MPJA_1:G]:H)C$?& Z"L5QTMV6MQ8Q 9>9A%_1_<"D71)+..Z6[?.Z]=-^O9M MD&W#T+"D\Y,#INV7A60P9CE,)1)'O[-A_C!$OK)!]GKATB('^H),QZ(.6_ @ M,MBK4B@A'KB+GR_Z)CB,T)H OIQLHSTAA?*E!A+CL0A4W(^LJQ)=4_?S?AHT3#Y,N MN.3TO([,RP9P",."."4>BD.96XE!X9"(1=R:6_FP5F1]U@F8E0])3S[4+7[2 M SL7A[^\QFQCJ];I+(MW=!\+':%SV2ZG7A?O>(F<6$[+QLD+Z$I8GNK+R^P* M(:&$Q;WV_LNDAUMW*S_6BJS/.@&S\N-@L?PH4^I@Z[=2A#3/4X.G;BU5:[^W M%)FCZ*O(DC@.)_;DE\D2K^XR6;+ZL%4$?&0OB$=TMI4F@\+\X=>,9TU6QMB'[&UH<6.6AUGQK$DJTAF MAX=MWUMX,>NE/V2>+$D9.Z3-4:]M:'MLM\)VEE[6K_B'S!++'@47$_;5,$CS M@4K@R43D?^6DV[(XMZ<<1X+8YJ)IH4EY[QUX"-67G7AX[YW^& Z_[$S-^U_7 MQL_;[B\G_U Z>-9,7=%)IM,ALYD^A[(N#&^Q,TC?$,!"'!CZ/PX. 3S$ ;ZG M:;L&PF!=2%W&L9YD=F7RQ[&K8)P+ROE9,IG^:'8-=-A]K7_+@A]":DOUM,NR M;4R^)/&=OZ6'/+P+2YZ7>ZII)VH7Z?2'L.3LR^!,U\Z_![YH3$*@J:DB/2W; M)L9QHTO)>L0VJE3R6RT]DVA:N99F%+SL:.+[7X]#\[%\DZBH]8<_XK.7XWQ> M6[MPW$F\0SXXYL?[ )$+T>6KK;#\*[Q[\#[Z^C6,VVS(YM69F7ZRGX^$O@_C M+M#;=UM>_+N*.[<6BEN+VXZDMX;?#Y\_R>"S*.ZOO#,SR.H/,'&D,UKIR[*Z MPA(5P/#M$9+9WDU&R",:J)@?F#"SKY)0!(B!D1FM7=2UC(&MLH2'R;9:2A0I MN$-T][PK=S]6[,"/B,]LQH*GPF$\CO;8"*:.^)ZLV $_L]!6 0^PD]VTB=@.BPN !7(G+M3$&"I+H4S:38&-?,R4\>._-Y7?5DY\T6.!=_;\9F>\4=YML^3]E(?;Y,//=%K-'ZX\??D,,2_.7*YXOJ:2=4$9L>$9 MO/>7>QVV.WR9)&.O6+ER$07%(IG;:0Z&',(:EFT0>KK!\X$.N!"L%O3 V\_. M;CHD/$?HWFC"V(WCTD9\-0P(X&;K0(<.0)&%^X1"0Y"EDBZSS6R2S&_V8Z2R M>R85R5*HNY-=69:-C.])XVSDM(R,H#&O;NCD;3COK>GU%X&4S<(+,*8NR/AD MUU]\%),&9YMU[ @ /#EL PDT='O)78_YJ?K]921^C22?[$D.?SIG/YO3#^*8 M3\;/<-H\,T_B:@NB9<%1UG"'MQA[?%.@)P/F&_^^X>]?US,W+!:6'L-M#+(4 MJ#'Y6$ZSY2<>A>DE\BZK8\69UO>_"":2>KDEE%KU6T#M;!F<^]T=,1(3(ZB! MJ:/9E*G>FHDM;Q<8Z&R8,E^=YPVP+UA!Y+,.RE_0T3.=6KG)6]-W=^8.C_^& MZKGK'MA@95V.H#UF;+%7]T7H^S3BY][&]WP(;ZQX:^%H'WQMZ@!<"3^]?NA0(L M%% D 'U&6D04=,PY>I%\8Z/T& M6"P/'YE&%V#0:" M[%""\0(!^-2]ZD$.(J*.K([!;]?$9LCVL6X[Y+IM8K6/DWBN.>\9.'2KY#:' M:_>4_=T=?^+>[06--5J0VS!@6(JK=XZ]T M3B(B[,I M+.C&36^(VN;5-;GVZY-9F'S?,KG N MGU5SK:O&1UQ%O:&QB+_BS=6]+3V[.SRSPO81VEB5M YJC]RP& \,>C58J,_1H1&')SFV:EA MOO+>0:ZM^[SAIB:[A%O)^)[PW%7 M!TSGKJ5!/GG3?^TI3*3>F<1U8ITUG8Q5DG4ZRHQO]MFXF!;)1FG4);: =1VT M]Z5\9DFV>APE7R)0L:9,M:9DN3SBW?GE,\J62;9DS1QB1XDR/KV.93;S*L&= MJ<2G>]^2]44B5?$C5.-) YIQ+X[8!JX^?\@FVC:4$6/BJ&KWM&R00YK8/N*7 MC6304!D>H7*!_W(?2Y_>\[=\W.LD>*]Y._Q]*#S$2L[@(?>C<17-G5_=-;3! M RT5VG=VHU2ZOKJ\SDGEZ]K!Y>6P61DVSFKG [.4' V?]*OK7DPCMY5>/_I/ M=%@M#42UUDJ9>;7?.;_[<6=9W^V+VL\?6LH\;Y1JW>MDIUK)]0^4A('%!_-Z MF%"<1O+RKE/,T;O! MR%&$?&<8N[JX,952]^PRT>T]U(2'ZT[U5S=5U7XV[M3V39T.XX\U2WSA7^J3W3ZKW<*M5%/G\>Z/4%TO5.^?&J.63@S@II1J&D="7X0"57I=S)B3LU_P]02P,$% @ !*AN5] .Z,O( P MRPX !$ !P879M+3(P,C,Q,3$T+GAS9+U7;7/B-A#^WIG^!]5?.[9Y:7*! M@[NYDDF&&;C2D)>;?+F1[04TL257DH'TUW=E6P0P<$";\DG>?9Y]D5:KI?-Y MF<1D#E(QP;M.W:LY!'@H(L:G7>=A['X9]_I]AWS^]/-/!'^=7UR7W#"(HS:Y M%J';YQ/QD7RE";3)+7"05 OYD3S2.#,2<<-BD*0GDC0&#:@H/+7)A=>H!<1U MC[#["#P2\N&NO[([TSI5;=]?+!8>%W.Z$/)%>:%(CC,XUE1G:F6MMJR5O^/H M0Z;"%;EU.4S5A^4=^S8%?I5=4[Y03_2R!\&H]??%\Q7 RVS^]/NOP22Y_/!Z M%0_$\Y\P]M4@X+=7#ZI7N.RH< 8))7@87'4=DU^9WJ+I"3GU&[5:W?\V'(QS MG%, V\N8\9==\'JKU?)SK856D,M QM9TTS?J@"I8648M.X!G7&G*PPU\I%>$ M=?"%7R@WH&PG]+* ,@N-8 NG(/2F8NZC O&-I@5FRIU2FJ[ $ZJ"W&BIV K MJ:M %&Z#7/V:@MH)+50;A$C++<+&KJ':-VK#:;BUIMNL6^;HR^-P14KI/('( MU')NO5ZO_X8W,H8$N+X1,KF&"['!B5WQ/821S"HJY3+-=, M66,13!AGN>/RUM6):^Y89E+$9<[L^-O@JJ5,0?0'_Y2O4PD*Z7E" Q24_!)R MF!O2.,SBLZAO\1UBEG*[C97]M9?O#B8DO[1M4RE=1S'3-IU2-I,PZ3IFRUU[ MFM\Q;0^+R$*,AP.7-C^C[9TJ'5L35(85*Y6F@D9$"E(SO -KG:,(G6E#'ZVY M(<:/T^#4S)$"\3NF/##VWR-7K+)3<]TLS'=*^'KEI)IUQ]_L)OB] MW7$ZF+B0FO!*XSKTWA0OY4"$N:D#%//E6IYK1&Z]@6W76ZKH+=)3@GC;AM." ML+PS@MCSZNWRK_;!S2(OIF.=[GD]#SK=R?$AULI*S@YA_:W]%S'D9DX*XLDHAK%/LQWFG\38E'7<0%E\<@AF\M M@7+ RB<7,XY]QW\LB>!C+<*7$97YK%_S<%09@1S/J(0A)($9=4S09M@Y$LUB M?(1,Z]0R,]W43-EM[+),1/?Y8Q!E,L\)A[KBVTZ5[4@DE/&^AL0@<0^R0&$? MS@SZ5HH,A]_"'$/(H=3&Z [4\Q.5DG*M[L4HD^$,V]-:%IOIG<3X?U/L^$4M MX/(?4$L#!!0 ( 2H;E<]VXX'_ @ 'UH 5 <&%V;2TR,#(S,3$Q M-%]D968N>&ULU5U=<]LV%GWOS/X'5GV6]>%X=^/&[2B*W=$TB57+3;9]\4 D M)&$, 1H M*5_OP _9%+$)2G7ALD\.#)U )Q[#@CBD@#]X=?MFGH/6$C"V45G M<-+O>)CY/"!L>='Y<]8=S<:32<>3"K$ 4<[P18?QSJ^__.L'3__[\&.WZUT1 M3(-S[Q/WNQ.VX#][7]$:GWN_888%4ES\['U#-#1'^!6A6'ACOMY0K+#^(F[X MW#L[&?;G7K=;H]YOF 5<_'DSV=>[4FHCSWN]Q\?'$\8?T",7]_+$Y^MZ%B8=I-F'T]/N%CVAOW^H/>_ M+Y]G_@JO49]Z-L46D!NYX*F;9SV4CK[FO6W@=H7 MR(+/>O&762@IJ3I#6I)S&47RF?M(13VDDI$'(LQOW136-8>Z@V'W='"RE4$G M]2D26W"*;_#",_]KH_>M;M##&@?&V9[YJC?FNN=JGE&AE<"+BXZ!Z+J'IX/! MX)VI^:<<2.TVN@=+8CI@Q^OE6D7"3QNV@;.M #&F4IO@SJ+&5[H*X8=SW W( M&C/3V3M>TE VLGTMA*F>AO823,]:P>OSWC?6#?@:D2-)%TL[8!RUU%WC]=S8 M?13=?-'7YXHH/8YA5.#U>3&N1L=22\LX[9-X@4*JGMTIT^)YSOHP8<0,>*OT50<'*7-38;U121%EH,D59>!US>4GU$R4_A@C$Q(I#UO6MVC^U(]*&">X0[9/5H]$RCOI)S5/QKASGON<*=TY+FG4 MFN[@>&D^I,P6@J\KI4QDXZ419+751#H>%P$6>L;6?^)"N<3!14>)T!*R8X/& M%$EYO9@I[M^/MJ1.[RH6>5';K%?2*IORZ@,60;%:W'HK7[(4/R779,@0&_9% MG2A.#ZIL !7FEES+2LF!=/1 MMR]W.@]=.Z0!GLRP(%C^_1T)@9B2MWP:"G^E$\8,UU)?ZE=P9QL"&N/-D7& MP]R+7'(D]D^6_*$78!*/QOIJZ=?-J*0 MMB]R!:F6=J3)!(;0%45+N[8Y2*/%+3)]U;G2$>I^PM(79*,R\T) Y RR'5H? M$@8'"[=CQ0U>$JE$=&=Q'U#YX&$MTF@3JIF#TQVW;HP8"Q&]P1LN*DS((ENA M?8$P)/D[MY+_$2*AL*"[.JH?@%LAO(TSI/V9XXF*GE;)2*HZXA^B6Z&^E30D M_[_=RC];84K-@T#$:O7^(KX5%@"T(1/^\W8F7#Z8B8(.K;X/^R*MLR+/''+C MOV[=T%DWX8&.2=3PX0#<"@=LG"'MW[^%]IA$#EJ MI2,/A&ZT_*6D0?T=Y;R73!&U,ZO1OH; O60-.T0U6F\K65!G1XEN3"J]]<&4 M67!7IG4>V0*]+81!S1TEN#&QL:8O$)VP &]_Q[LRT0^@+5#=QAB4W5%B&S.; M"K)&8CN$T34[[23Q=J',6Q,CV:)\E#&KN-$U.B$VY5(C^3395LU,;OCWZ%VF#+CC* MFI,>86ZC0,NN27!XV'_=:&7S+"%)G[W!X4A)OPNB-!^SDCQD MR1TDX,F?%=IHJ6'&H.R.4LX9I\37"K'E%QV'((C:-2_B&BTX0!=4VU%V.171 M5@FL)_G18CBS@5=<+Q;02 WC&ZU^!6W0!4=IY@&]B90A%L=Z42C5)D?LY$%? M'*6<,^R'>J#<#8;S6[-%'1B)#E"-UMU*%M3949KYE=\*9-ZF,]NMYYS"6W@L MP$:K#?$%!7>44>98V:7.01HM$8:8KY.Y?5# M'8*J4LTVHPYYT!>GSTF_8TI_9_R1S3"2G.$@3BS*GE8 11KM2#5ST ZG3TZ_ M<1HRA42TY%8 YX85V@+Y;8Q!V9T^)$V6E>^O7/'+.\O4MY=H@0DEQ$$OG#X\ MG3"%!?(5><"?D$()WS(O["5:X$4)<= +IPN/HQ-UK.-9\O*U SE@"Y0O\@4% M=[K>>+9&E'X,I0Y EHX_.6 +!"_R!05WNJ+X^;I2;QG( %2 . MP/A&>U!!&W3!49I\K5989&=E$3433-E"D*I2C7:D%GG0%Z=IV!F]555>ARKZ>RJ:;>F-BY)R+;"IDC[H MCN-7408"Z M^7O]77+<_#!_ $8?^3]02P,$% @ !*AN5Q%R'(_P"P ") !4 !P M879M+3(P,C,Q,3$T7VQA8BYX;6S-G6]OV[H5QM\/V'?@O+VX ^HX=K8!R6WO M19HF%\%-DZQ.VZW%4- R;0N1Q8"2$^?;CW]$6:)X)#GM)=D7K2L]AWHH_DQ2 MLGCT^M?M.D&/A&4Q3=\,Q@>' T32B,[C=/EF\'$Z/)V>75X.4);C=(X3FI(W M@Y0.?OWESW]"_,_KOPR'Z"(FR?P$O:/1\#)=T)_1-5Z3$_0;20G#.64_HT\X MV8@M]")."$-G=/V0D)SP'>K )^B?!Y/#&1H.>Y3[B:1SRCY^N"S+7>7Y0W8R M&CT]/1VD]!$_47:?'41TW:_ :8[S35:6=K@]+/ZH\-=)G-Z?B+]F.".(GZ\T M.]EF\9N!.&YQV*>C \J6H\GAX7CTG_=7TVA%UG@8I^*\162@HT0IMKCQ\?'Q M2.[5TH9R.V.)/L;12-LI2^9[XQ9]Q4D6GV32WA6-<"Z;O?,P"%2(_PVU;"@V M#<>3X='X8)O-!_KDRS/(:$(^D 62U3S)GQ\X2EDL2!@4VU:,+.QF$L9&(GZ4 MDB7.R5PULHJ@D6NSMX3%='Z>OLRU M&>W)/O_NL/P[*E"-=UZ%.YKCY$7FJY'.;5^3EYWQ79S[,\W[>?*R,UV)_$-L MYTW+>Y]>^WE-Q,8K_JEFD6QS/H"1N38IBFCI@>41Y,!0E%V63J-:N8GHS2EK MUEV,C++,!^I%9 1%YRG0M,(LZ3D6A&$64#V0/^3!1)UV%+QA= M][)1G#/:0_PMF97EJY/,+0 5JB&162O-J[6IN]9+1RN$QXA)FPD'7Z< M#GZ1,D072 K15R']W^O1KNB7L/2 ']<2D/%X_ \)R>WII_??^&1N35-YH%O, MY!SJ\(!/@WC_/EUA1MZ3]8PPHV)[1;H YP55$0CM$>8=IOV]-K"2P0JJ5XC' MJRDS^ILL O$RD"SD#R)MRF<,)/OR&3.&TSR[H[?\M*SXM+-2*9BV?:*=$;=_ ME4KJ^H>&0=[>?DWZ5 'H"])%H)PB70BJLOF]_/VX4?,.SW;3$:A3+T1>QL>: M0>N@*!7>$6JUU2!%B]!7*?ONH>_' <&G@^22?^RYH ALZ6U! F-XP8^Y0>>BX-?)'AIL6_L=]7$5ENZC6L[@VADFR.SE4L- M$B)?S?R.9!&+'\1MU;9ZU&3.&]UBLM'V%4U8"#2-P214M)XZ]@]D&6.3M-T@Y,/Y(&R-GSJ,M?4 MV$R:L%0U03%B,0:BH;1(B3T1\>\-9CEAR7,G% VE:RX JR8:ABPH.NS>0$!* MN5]&[AA.LUAT8)V0-*7.+S< LXU+#T,7%"> .?B2I-3[)66Z(DDBGLO :7>' M8A.[I@4V;/+25 9%#&@/9$9&H"(D'&S.'\7LG$^3>E:VHO<)3\-V&S^E.%B$ M3(<]*9)A2,1Y(JGR.$@'0PVE:WH JR8WABPH8NS>0%:4'$F]?TC.TWDO1$J= M'T ,FW8\"E& <-2==:'!U3[!N(BS""?*RP7?9OZ\TJ%U#0AHUX2D(0P*%,@= M"(L*T,S($*_ _)=@U@^7BM(/+ VK=E1*68"@F-ZZ,!%Z+Y"<;1BKN89''%CJ M"I,NLYH32!<$*!WF&@\B*7D-%$\CT'F:Q_FS6-=PO;$\>F27N&(#,J>9,/<' MP0)@RF1 R9#0(27TTO+Z5X(T%XM)P.J8,K<$V$W6*:AK B+!:@R@8:>5:WN\ M$''&>R:&D\MT3K:_DV>P7@V=6R8 FW4H#%% 5-B= 5@48B35B,N]@''+XC5F MS],XZA@JFD*W:$!&ZVR8JH#@ *P!=!1J-+T\\SF2W.'MY9R#&B]BM2ZO@Q)0 M[Q:6#MMU9@!Q0.BT.P0(XD&H'N43I,LTHNR!5AYW.*,;W@$^G]$Y/$/IB'(+ M5:\JU-%J#0D(L#X^ X ?@KE*_T!B1ATDX8"S62/JD[\0S/I"\TD:&@F+X'F M[HD& LW1'E4]\@_-45]HCH*&YNA%T/"&]]K7G/&/-^R./MD>S@:57I!I6K4" MLY.%ATO#6Q^QHU*>_\DFB9GUZF;M+>Q2A->)#4C75V+DKM$XE;FN4X^1(_M%Z( MV\5>\+ :MD)24X:'BLU>%S J!O$@'Q?6!:[B!PWK4C)CO[-?FVVVRI^8JSN# M@,#FJ)G50MT]42+7S2P8900#/4)]M[-&MI@JV[BR+XPF;AIJM+#\7G.-CR^R MR+*7W*YH"C\@T)2X:FG(G&YM;H;+S)]9?;NN[+/VVW.#@,Y5*[?:U"UN%071 M^FW.3!(*+:J+'6,QI4D$!PZ@2 M@50(DC%^L;G,L@UA>\%C"?&$$&@> *FA#Q$GR&0G5"K0)UM3$FWX^/@\GLSN MXKR1A,XN<38F >;*$_UM:>NOSS;;3BI@BP(,$N<]WUVTR:W7]5$P0"+<::V6J5%&FM MCP4)NR%KV3T)6'J;!"P[)@'+$"_X!\LM01TSG):MMDL MDUK:1$$PTN:LD=92)9VKB)%0N^9B,X]S,E=F+N(4IU&,DS(]HNV.>'>(,UIZ MFB_!Z="'P5 _DPV<5)C.95@&[E)=NKZ5KA[ ^$R2Y/>4/J53@C.:DKFZEV+[ MI:A=[_:)F0[;]8=F '$0./5Q"#PZ(X*&]R(*Z;#B3I@7DC[19)/FF,FUY,S6 M,P$ZM^0 -NO$&** 2+$[ P@IQ4BI_2S05MDCRDF6>O\C6$%([GBY=JMI8]6V M51L0,ZT&H37<1F%ANL9)\G:3Q2G)X('(4+EEP6JQSD)-$A +-E\ "U**M-8+"^=KPI9\ M>/N-T:=\5>1G!>L&J-VRT6JYSHA5&A K;?X 9G0(4C$ZI:X?>+:[A.(JRR)< M4XO4,3:@68.9ABXD8"!S#5H2$HG[+=O ZYF@E?E^'K3 M2!2)!1%J5I[.,;,AU"9V_M81T'#CW2,-91 @==J#WT-21B =XIB:&\XPJU[' M21/B77K@:H?N$%<$]36O.>K2!T%33Y,F4S*L?G$M ^5[$7UF,ZHFMX>G>#61 MXYFQQ: Q,:XH@F $M 5-BZOO"O"3.V\S2^+H(J$8OLM2TSC.F->T9R3+VPD" M(J#I"DJ1)X5(*KVT_UNLLK*WJKK_EO/:+?,[%6E.DV] M0@/B;!^_ (&[(E"EC%>5$OZZJUW=A:@%H)IX1*XI 7T4A2)9B>W]Y M==,5_\0WZTW\KQG."-_R?U!+ P04 " $J&Y7>AWBDD$( 78P %0 M '!A=FTM,C R,S$Q,31?<')E+GAM;-6=77/:.!2&[W=F_X.7O29 LE]-F]U) M:=)A^A$VI.UN;SK"%J")+#&2G,"_7\E@ MB2#]LMQ]N+A)@CZ;S/D64=6W)? M_+%(>?1 E6927+1Z)]U61$4L$R:F%ZT/H_;EJ#\8M")MB$@(EX)>M(1L_?'[ M]]]%]M^+']KMZ)I1GIQ'KV3<'HB)?!Z])RD]CUY3014Q4CV//A*>N2/RFG&J MHKY,YYP::K]8-7P>_7QRVAU'[3:@WH]4)%)]N!ULZIT9,]?GG<[CX^.)D _D M4:I[?1++%%;AR!"3Z4UMW45W_6]5_ 5GXO[<_1@332/+2^CSA687+=?NNMG' MLQ.IIIW3;K?7^>O=VU$\HREI,^&XQ;15E'*U5)7K/7OVK)-_6YB6+!=CQ8LV MSCJ%.YN:[;VTSDM7!_M0NSMCO4[IVVSWHG"YVT M"O@Y024YO:63R/VVT=NT.BE:6V)?MQ9;EVHW"$RWBG;>[HRSVA14_.&6L:GTSE0R>AK./$ MNP\YA9R _>-+WM#E6!M%8E/4Q,F8\KS^+]9FSZ3SU5Y-B![GX<]T>TK(?.4: MY4871YY\7!_XXLXPZN#&^W;ZWV\&\5+N>$Q47%=N/.Y$L]]JU MA8VQLO6UXQGCFTXP43+UX5LW*(->2Y509=M^WQ=& _:@#S+5MD[AZN M8?A;[J\#<-J /0YT?IF,C(ROK]<,$@&:G:5O>!6-R2 7 N)SAQN5P)%\;FP-G=,4L\L[66#VAV[4 8O]6U/T3 MC8)ZR6,4K)>V_<3Y<,W)M)KKG@D0; ^5;*4L++2OJ(X5FSM -81W++$'],- M5XA$&B%NZ92YM,2YLM$0'C(\1;"'[H,&D:!LI%!<"I$1?DOG4M5$8-<2"/ZG M1H"O$HG$^\^,*$,57T*0EXR!U']N!'6/5*Q9B9TU:>9 0I]8 M)/:C&>771M MCU7=1-YRO<(M6=D*"ALWG?6I0X%MX3" MQLUB0RI1@/>MPXKP@4CHX@U=AHB73*'(<;/7H$X4YD/%4J*6(Q;7CR=E6RAU MW)PUK!0%^QU9#!+K-INPU3*O>OK>(M @X":L(-THL1B(6*JYW+IKW9>9/4.7 M?9D$A_V:@M"XX&:R!S! BOW+*>F%8E)I#GZ*U8!(!/0VA/_I8?Q/ MX?QQ,]Q:O0WA?W88_S,X?]PLMU8O)O^^_7BC[N2CY_&YUQC*'C?+K=&*23[W M_T8-E7Q@JS7R=?A+): Q:$+R&U:->@JL9@20_E]80L$W(1&N5HD)?"BU(?PS MF]=-1*OMH?";D!*'%!_[]N:J [C[(KZU4GLF4-"X67"EKF.S=:%6E/@[]*X% ME"QN:ENEZLA@WTKW4&8F1?"V<-D*"A@W1_6I._;@[#:D:>^HL/4U>-$>[M"[ MK^?(/#\I9JP';G5W)M;W@SP/\#RF4,ZXB650YY&9CR1G,3-,3-]9SQ4CO!IX ME1V4-FX:Z5=X9-1#E6]9]*D[,N3W\DX1 M]YZ(T3(=2^[?65-I"$6-FSH&-!Z9]HX?U9SW3*"$<7/&2EU(P\75(IX1,:7^ MQ1C5EE#2N#ED2"7:^#P%C<_3 \=GW%S2IPX)\FKMO#W';L:<38E_?UZP 'BO M4B/0!S0?>WMDOFW*O6Y(I;D?U_9#-7^/*90\\E;4D,YC,\\29FBR:\J4#W*?8=5(2_(,=>_T8@_T%3%D[6$H$+X2T$ TX2%H6#7:1@/5MPJF,OSD?\\0 MBKT)"X,K-:+0'J6$\Y>9MB[KX+"S9PBEW805P)4:46A?I51-[7CW6LE',UOO MH0U1]Q2 TF_".M^@9IPH+)ZV\J]V%09#4&$-?F5$$_A[U6*]'26.W;J0U65? M)$1Y\(?LH0%HQ@96O^(CA^#&S*C:GG7ESCCW0VLXZDM!PX&;"$/5XUR(M]ZJ M$+P.[]A!P3G/^ 3(L8 70V#0A\SV(" M90$ "@ @ $ 97@Y.2TQ+FAT;5!+ 0(4 Q0 ( 2H M;E?W4V^2#A0 'VH + " 8LB !F;W)M."UK+FAT;5!+ M 0(4 Q0 ( 2H;E?0#NC+R , ,L. 1 " <(V !P M879M+3(P,C,Q,3$T+GAS9%!+ 0(4 Q0 ( 2H;E<]VXX'_ @ 'UH 5 M " ;DZ !P879M+3(P,C,Q,3$T7V1E9BYX;6Q02P$"% ,4 M " $J&Y7$7(&UL4$L! A0#% @ !*AN5WH=XI)!" %V, !4 M ( !"U '!A=FTM,C R,S$Q,31?<')E+GAM;%!+!08 ..!@ & 'D! !_6 ! end